Abnormal bone metabolism in Crohn's disease.
Inflammatory bowel diseases (IBD) including Crohn's disease (CD) and ulcerative colitis (UC) have a major impact on the health of individuals and populations. These diseases result from an inappropriate immune response, in genetically susceptible individuals, to microbial antigens of commensal microorganisms. This paper reviews the abnormal bone metabolism associated with CD, in order to elucidate the mechanism of bone loss.
Institute of Digestive Disease, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Tao
T
Wu
Hai Yan
HY
Song
Guang
G
Ji
D000305:Adrenal Cortex Hormones / Q000009:adverse effects; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001851:Bone Diseases, Metabolic / Q000209:etiology / Q000378:metabolism / Q000628:therapy; D016723:Bone Remodeling / Q000187:drug effects; D001842:Bone and Bones / Q000187:drug effects / Q000378:metabolism*; D002118:Calcium / Q000172:deficiency / Q000378:metabolism; D003424:Crohn Disease / Q000150:complications / Q000188:drug therapy / Q000378:metabolism*; D005260:Female; D006801:Humans; D000069285:Infliximab; D008297:Male; D008954:Models, Biological; D012307:Risk Factors; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D014807:Vitamin D / Q000378:metabolism; D014808:Vitamin D Deficiency / Q000150:complications
D000305:Adrenal Cortex Hormones; D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D014807:Vitamin D; D000069285:Infliximab; D002118:Calcium